• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Age Related Macular Degeneration - Pipeline Review, Q2 2011 - Product Image

Age Related Macular Degeneration - Pipeline Review, Q2 2011

  • Published: April 2011
  • 114 pages
  • Global Markets Direct

Age Related Macular Degeneration - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Age Related Macular Degeneration - Pipeline Review, Q2 2011', provides an overview of the Age Related Macular Degeneration therapeutic pipeline. This report provides information on the therapeutic development for Age Related Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration. 'Age Related Macular Degeneration - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Age Related Macular Degeneration.
- A review READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Age Related Macular Degeneration Overview
Therapeutics Development
An Overview of Pipeline Products for Age Related Macular Degeneration
Age Related Macular Degeneration Therapeutics under Development by Companies
Age Related Macular Degeneration Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Age Related Macular Degeneration Therapeutics - Products under Development by Companies
Age Related Macular Degeneration Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Age Related Macular Degeneration Therapeutics Development
Alcon, Inc.
Genzyme Corporation
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Allergan, Inc.
QLT Inc.
Advanced Cell Technology, Inc.
GlaxoSmithKline plc
Santen Pharmaceutical Co., Ltd.
Oxford BioMedica plc
Lux Biosciences, Inc.
Light Sciences Oncology, Inc.
Optherion, Inc.
Novartis AG
Pfizer Inc.
VasGene Therapeutics, Inc.
Shire Plc
ISTA Pharmaceuticals, Inc.
Alchemia Limited
iCo Therapeutics Inc.
InNexus Biotechnology Inc.
Lpath, Inc.
ReGenX Biosciences, LLC
Ophthotech Corp.
OXiGENE, Inc.
Alexion Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Progen Pharmaceuticals Limited
Sirion Therapeutics, Inc.
Summit Corporation plc
Sucampo Pharmaceuticals, Inc.
ThromboGenics NV
Simcere Pharmaceutical Group
PolyMedix, Inc.
e-Therapeutics plc
NanoCarrier Co., Ltd.
R-Tech Ueno, Ltd.
Paloma Pharmaceuticals, Inc.
Digna Biotech, S.L.
Ceregene, Inc.
CoMentis, Inc.
StemCells, Inc.
Ora Bio Ltd.
Molecular Partners AG
Acucela Inc.
Acceleron Pharma, Inc.
Applied Genetic Technologies Corporation
Neovacs SA
Cosmix Molecular Biologicals GmbH
MAT Biopharma
InCode BioPharmaceutics, Inc.
OcuCure Therapeutics, Inc.
Neurotech Pharmaceuticals, Inc.
Gene Signal International SA.
Promedior, Inc.
Iconic Therapeutics, Inc.
Inotek Pharmaceuticals Corporation
Indus Biotech Private Limited
Othera Pharmaceuticals, Inc.
Cardax Pharmaceuticals, Inc.
NOXXON Pharma AG
Adeona Pharmaceuticals, Inc.
Angstrom Pharmaceuticals, Inc.
Alimera Sciences, Inc.
Taiwan Liposome Company
Biovista Inc.
Resolvyx Pharmaceuticals, Inc
Allostera Pharma Inc.
Charlesson LLC.
KAI Pharmaceuticals Inc.
TaiGen Biotechnology Co., Ltd.
Kemin Industries, Inc.
OHR Pharmaceutical Inc.
Steba Laboratories Ltd.
Age Related Macular Degeneration - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
VEGF Trap-Eye - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-8309B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis + Visudyne - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Visudyne + Lucentis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Verteporfin Photodynamic Therapy + Ranibizumab + Triamcinolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis + Visudyne - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Verteporfin + Triamcinolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Verteporfin + Pegaptanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Verteporfin Photodynamic Therapy + Triamcinolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Age Related Macular Degeneration Therapeutics – Drug Profile Updates
Age Related Macular Degeneration Therapeutics - Discontinued Products
Age Related Macular Degeneration - Featured News
Apr 07, 2011: Lpath Initiates Enrollment Of iSONEP Phase Ib/IIa Proof-of-Concept Trial
Apr 05, 2011: Neurotech's NT-501 Implant Slows Vision Loss In Patients With Geographic Atrophy Associated With Dry AMD As Reported In PNAS
Mar 01, 2011: Paloma Pharmaceuticals Provides Update On Ocular Clinical And Oncology Programs
Feb 22, 2011: Regeneron Submits Biologics License Application To FDA For VEGF Trap-Eye For Treatment Of Wet Age-Related Macular Degeneration
Jan 03, 2011: ACT Receives FDA Clearance For Clinical Trials Using Embryonic Stem Cells To Treat Age-Related Macular Degeneration
Nov 30, 2010: Advanced Cell Technology Files IND With FDA For Phase I/II Clinical Trial Using Embryonic Stem Cells To Treat Dry AMD
Nov 22, 2010: Bayer And Regeneron Report Positive Results From Two Phase III Studies With VEGF Trap-Eye In Wet Age-related Macular Degeneration
Nov 10, 2010: ChemoCentryx Presents Positive Phase I Results For CCX168 At Annual American College Of Rheumatology Meeting
Nov 09, 2010: Oxford BioMedica Receives FDA IND Approval For RetinoStat In Wet Age-Related Macular Degeneration
Oct 18, 2010: Phase IIb Data Suggest ReVision’s Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Age Related Macular Degeneration, Q2 2011
Products under Development for Age Related Macular Degeneration – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Alcon, Inc., 2011
Genzyme Corporation, 2011
Johnson & Johnson, 2011
F. Hoffmann-La Roche Ltd., 2011
Abbott Laboratories, 2011
Allergan, Inc., 2011
QLT Inc., 2011
Advanced Cell Technology, Inc., 2011
GlaxoSmithKline plc, 2011
Santen Pharmaceutical Co., Ltd., 2011
Oxford BioMedica plc, 2011
Lux Biosciences, Inc., 2011
Light Sciences Oncology, Inc., 2011
Optherion, Inc., 2011
Novartis AG, 2011
Pfizer Inc., 2011
VasGene Therapeutics, Inc., 2011
Shire Plc, 2011
ISTA Pharmaceuticals, Inc., 2011
Alchemia Limited, 2011
iCo Therapeutics Inc., 2011
InNexus Biotechnology Inc., 2011
Lpath, Inc., 2011
ReGenX Biosciences, LLC, 2011
Ophthotech Corp., 2011
OXiGENE, Inc., 2011
Alexion Pharmaceuticals, Inc., 2011
Regeneron Pharmaceuticals, Inc., 2011
Progen Pharmaceuticals Limited, 2011
Sirion Therapeutics, Inc., 2011
Summit Corporation plc, 2011
Sucampo Pharmaceuticals, Inc., 2011
ThromboGenics NV, 2011
Simcere Pharmaceutical Group, 2011
PolyMedix, Inc., 2011
e-Therapeutics plc, 2011
NanoCarrier Co., Ltd., 2011
R-Tech Ueno, Ltd., 2011
Paloma Pharmaceuticals, Inc., 2011
Digna Biotech, S.L., 2011
Ceregene, Inc., 2011
CoMentis, Inc., 2011
StemCells, Inc., 2011
Ora Bio Ltd., 2011
Molecular Partners AG, 2011
Acucela Inc., 2011
Acceleron Pharma, Inc., 2011
Applied Genetic Technologies Corporation, 2011
Neovacs SA, 2011
Cosmix Molecular Biologicals GmbH, 2011
MAT Biopharma, 2011
InCode BioPharmaceutics, Inc., 2011
OcuCure Therapeutics, Inc., 2011
Neurotech Pharmaceuticals, Inc., 2011
Gene Signal International SA., 2011
Promedior, Inc., 2011
Iconic Therapeutics, Inc., 2011
Inotek Pharmaceuticals Corporation, 2011
Indus Biotech Private Limited, 2011
Othera Pharmaceuticals, Inc., 2011
Cardax Pharmaceuticals, Inc., 2011
NOXXON Pharma AG, 2011
Adeona Pharmaceuticals, Inc., 2011
Angstrom Pharmaceuticals, Inc., 2011
Alimera Sciences, Inc., 2011
Taiwan Liposome Company, 2011
Biovista Inc., 2011
Resolvyx Pharmaceuticals, Inc, 2011
Allostera Pharma Inc., 2011
Charlesson LLC., 2011
KAI Pharmaceuticals Inc., 2011
TaiGen Biotechnology Co., Ltd., 2011
Kemin Industries, Inc., 2011
OHR Pharmaceutical Inc., 2011
Steba Laboratories Ltd., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Age Related Macular Degeneration Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Age Related Macular Degeneration, Q2 2011
Products under Development for Age Related Macular Degeneration – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Discovery and Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos